Imipramine
Imipramine (imipramine) is a small molecule pharmaceutical. Imipramine was first approved as Janimine on 1982-01-01. It is used to treat attention deficit disorder with hyperactivity, depressive disorder, enuresis, pain, and panic disorder amongst others in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target G protein-activated inward rectifier potassium channel 2, muscarinic acetylcholine receptor M2, voltage-gated delayed rectifier potassium channel KCNH1; potassium voltage-gated channel subfamily H member 1, and G protein-activated inward rectifier potassium channel 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Imipramine, Imipramine pamoate (discontinued: Imipramine, Imipramine pamoate, Janimine, Pramine, Presamine, Tofranil, Tofranil-pm)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Imipramine hydrochloride
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| imipramine hydrochloride | ANDA | 2025-11-19 |
| imipramine pamoate | ANDA | 2025-05-30 |
| tofranil | ANDA | 2016-12-23 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 2 | 2 | 1 | 5 | 5 | 14 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | 2 | — | 5 | 3 | 10 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | 3 | 3 | 7 |
| Dental caries | D003731 | EFO_0003819 | K02 | — | — | — | 4 | — | 4 |
| Dysthymic disorder | D019263 | EFO_0008623 | F34.1 | 1 | 1 | — | 2 | — | 3 |
| Child behavior | D002652 | — | — | — | — | — | 3 | — | 3 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | 1 | 1 | 2 |
| Panic disorder | D016584 | EFO_0004262 | F41.0 | — | — | — | 1 | 1 | 2 |
| Atrophy | D001284 | — | — | — | — | — | 1 | — | 1 |
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stress urinary incontinence | D014550 | — | — | 1 | — | 2 | — | — | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 2 | — | — | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 2 | — | — | 3 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | 1 | 2 | — | — | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | 1 | 2 |
| Somatoform disorders | D013001 | — | F45 | — | 1 | 1 | — | — | 2 |
| Ventricular fibrillation | D014693 | EFO_0004287 | I49.01 | — | — | 2 | — | — | 2 |
| Ventricular tachycardia | D017180 | — | I47.2 | — | 1 | 1 | — | — | 2 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | 1 | — | 1 | 2 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | 1 | — | — | 1 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Photochemotherapy | D010778 | — | — | 2 | 1 | — | — | — | 3 |
| Actinic keratosis | D055623 | — | L57.0 | 1 | 1 | — | — | — | 2 |
| Keratosis | D007642 | — | — | 1 | 1 | — | — | — | 2 |
| Dental anxiety | D016854 | — | — | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Rosacea | D012393 | — | L71 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary incontinence | D014549 | — | R32 | 1 | — | — | — | 1 | 2 |
| Fecal incontinence | D005242 | — | R15 | 1 | — | — | — | — | 1 |
| Photosensitivity disorders | D010787 | — | L57.1 | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Taste disorders | D013651 | — | — | — | — | — | — | 3 | 3 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Generalized anxiety disorder | D000098647 | — | — | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Myalgia | D063806 | — | M79.1 | — | — | — | — | 1 | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 1 | 1 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 1 | 1 |
| Metabolome | D055442 | — | — | — | — | — | — | 1 | 1 |
| Allergic rhinitis | D065631 | — | J30.9 | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Imipramine |
| INN | imipramine |
| Description | Imipramine is a dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom. It has a role as an adrenergic uptake inhibitor, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor and an antidepressant. It derives from a hydride of a 5H-dibenzo[b,f]azepine. |
| Classification | Small molecule |
| Drug class | antidepressants (imipramine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCCN1c2ccccc2CCc2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 50-49-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL11 |
| ChEBI ID | 47499 |
| PubChem CID | 3696 |
| DrugBank | DB00458 |
| UNII ID | OGG85SX4E4 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNH1
KCNH1
Organism
Homo sapiens
Gene name
KCNH1
Gene synonyms
EAG, EAG1
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily H member 1
Protein synonyms
EAG channel 1, ether-a-go-go 1, Ether-a-go-go potassium channel 1, ether-a-go-go, Drosophila, homolog of, h-eag, hEAG1, potassium channel, voltage gated eag related subfamily H, member 1, potassium voltage-gated channel, subfamily H (eag-related), member 1, Voltage-gated potassium channel subunit Kv10.1
Uniprot ID
Mouse ortholog
Kcnh1 (16510)
potassium voltage-gated channel subfamily H member 1 (Q60603)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Imipramine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 20,040 documents
View more details
Safety
Black-box Warning
Black-box warning for: Imipramine hydrochloride, Imipramine pamoate, Tofranil
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,789 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use